UNSPSC 51312801: Dacemazine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H16N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88D34UY0QI, chemically known as 10-n,n-dimethylglycylphenothiazine but generally known as dacemazine, which bears US NIH Compound Identifier 68846. European Medicines Agency schedules Dacemazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06883MIG. The term DACEMAZINE is an International Non-Proprietary Name.

UNSPSC 51312801 Dacemazine, a Commodity code, nominally targets a specific pharmaceutical active ingredient, but recent state and local solicitations tagged under this code reveal that purchasing bodies are actually seeking broader pharmaceutical procurement — generic multi-source drugs, naloxone, drug deactivation systems, and over-the-counter products supplied through established wholesaler networks and direct-to-manufacturer channels. State and local health and human services agencies, county health departments, and cooperative purchasing alliances are the primary issuing bodies. Seminole County, Florida and the Texas Health and Human Services Commission represent the mix of local and state actors. Work scoped under the code ranges from direct procurement of naloxone and safe drug deactivation systems in support of community health initiatives to cooperative purchasing agreements for generic pharmaceuticals across multiple jurisdictions, with vendors required to meet cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized wholesalers, and provide detailed product coding and pricing documentation.

Activity is concentrated in Florida and Texas, with broader multi-state reach through cooperative purchasing vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which serves participating state and local government facilities including Oregon. The Minnesota MMCAP RFP for Generic Multi Source Pharmaceuticals and Over the Counter Products (S1070000015802), posted January 20, 2026 with response due March 26, 2026, seeks manufacturers to supply products through three authorized wholesalers with awards effective July 1, 2026, evaluated primarily on price competitiveness (75 percent weight) and compliance with EDI capability and cGMP certification. Seminole County's IFB for Naloxone & Drug Deactivation Systems (IFB60459723LAS), posted June 30, 2026 with response due July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas HHS Commission's RFI (HHS0017013) for Direct-to-Manufacturer Prescriptions, posted April 3, 2026, represents exploratory market intelligence gathering to inform future formal procurement for direct-contracting pharmacy benefit programs.